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In Brief
Hexanucleotide expansions in C9ORF72
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feasibility of ASO-mediated therapy.
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Hexanucleotide expansions inC9ORF72are themost
frequent genetic cause of amyotrophic lateral scle-
rosis and frontotemporal dementia. Disease mecha-
nisms were evaluated in mice expressing C9ORF72
RNAs with up to 450 GGGGCC repeats or with one
or both C9orf72 alleles inactivated. Chronic 50%
reduction of C9ORF72 did not provoke disease,
while its absence produced splenomegaly, enlarged
lymph nodes, and mild social interaction deficits,
but not motor dysfunction. Hexanucleotide expan-
sions caused age-, repeat-length-, and expres-
sion-level-dependent accumulation of RNA foci and
dipeptide-repeat proteins synthesized by AUG-inde-
pendent translation, accompanied by loss of hippo-
campal neurons, increased anxiety, and impaired
cognitive function. Single-dose injection of antisenseoligonucleotides (ASOs) that target repeat-contain-
ing RNAs but preserve levels of mRNAs encoding
C9ORF72 produced sustained reductions in RNA
foci and dipeptide-repeat proteins, and ameliorated
behavioral deficits. These efforts identify gain of
toxicity as a central disease mechanism caused by
repeat-expanded C9ORF72 and establish the feasi-
bility of ASO-mediated therapy.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia
(FTD) are two devastating adult-onset neurodegenerative dis-
eases with distinct clinical features but common pathological
features and genetic causes (Ling et al., 2013). Hexanucleotide
GGGGCC repeat expansions in a noncoding region of the
C9ORF72 gene are the most common inherited cause of ALS
and FTD (DeJesus-Hernandez et al., 2011; Renton et al., 2011).Neuron 90, 1–16, May 4, 2016 ª2016 Elsevier Inc. 1
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cause disease (referred to as C9ALS/FTD) include loss of
C9ORF72 protein function and gain of toxicity (Gendron et al.,
2014; Ling et al., 2013).
A reduction in C9ORF72 function (i.e., haploinsufficiency) is
supported by decreased expression of C9ORF72 mRNAs in
patient tissues resulting from DNA and histone hypermethylation
with partial silencing of the repeat-containing allele (Belzil et al.,
2013; DeJesus-Hernandez et al., 2011; Gijselinck et al., 2012; Liu
et al., 2014; Xi et al., 2013, 2015). RNA gain of toxicity has been
proposed to arise from folding of repeat-containing RNAs into
stable structures that sequester RNA-binding proteins to nuclear
RNA foci, a mechanism originally established for myotonic dys-
trophy (reviewed by Wojciechowska and Krzyzosiak, 2011).
Indeed, foci containing sense GGGGCC or antisense GGCCCC
repeat RNA are present in tissues from C9ALS/FTD patients
(DeJesus-Hernandez et al., 2011; Gendron et al., 2013; Lagier-
Tourenne et al., 2013; Mizielinska et al., 2013; Mori et al.,
2013a; Zu et al., 2013). Several RNA-binding proteins appear en-
riched in sense RNA foci (Cooper-Knock et al., 2014; Donnelly
et al., 2013; Lee et al., 2013; Mori et al., 2013b; Sareen et al.,
2013; Xu et al., 2013), but evidence supporting a loss of function
of these proteins is lacking.
Another proposed disease mechanism from C9ORF72 repeat
expansions is the production of aberrant dipeptide-repeat (DPR)
proteins through repeat-associated non-AUG-dependent (RAN)
translation, a phenomenon discovered in spinocerebellar ataxia
type 8 and myotonic dystrophy (Zu et al., 2011). In C9ALS/
FTD patients, five DPR proteins—poly(GA), poly(GR), poly(GP),
poly(PA), and poly(PR)—are produced from all reading frames
of either sense or antisense repeat-containing RNAs (Ash
et al., 2013; Gendron et al., 2013; Mori et al., 2013a, 2013c; Zu
et al., 2013). DPR proteins form p62-positive, TDP-43-negative
inclusions, with poly(GA), poly(GP), and poly(GR) aggregates be-
ing the most abundant (Mackenzie et al., 2014; Mori et al.,
2013c). Poly(GP) and poly(GA) can also be detected by immuno-
assay in patient-derived cultured cells, postmortem tissues, and
cerebrospinal fluid (Gendron et al., 2015; Su et al., 2014; van Blit-
terswijk et al., 2015). Overexpressing (Mizielinska et al., 2014;
Wen et al., 2014; Yang et al., 2015) or exogenously exposing
(Kwon et al., 2014) cells and other model systems to high levels
of arginine-containing DPR proteins induces rapid cell death.
Other studies have reported poly(GA) to be particularly prone
to aggregation and to confer toxicity (Gendron et al., 2015;
May et al., 2014; Schludi et al., 2015; Zhang et al., 2014, 2016).
Lastly, a recent flurry of studies found that nucleocytoplasmic
transport is impaired in C9ALS/FTD (Boeynaems et al., 2016;
Freibaum et al., 2015; Jovicic et al., 2015; Zhang et al., 2015,
2016), although the exact roles of RNA foci and/or DPR proteins
in this pathway are not yet resolved. Indeed, divergent outcomes
were reported regarding the toxicity of repeat-containing RNAs
or DPR proteins in cell culture (Devlin et al., 2015; Kwon et al.,
2014; Lee et al., 2013;May et al., 2014; Rossi et al., 2015; Schludi
et al., 2015; Wen et al., 2014; Zhang et al., 2014; Zu et al., 2013),
flies (Freibaum et al., 2015; Mizielinska et al., 2014; Tran et al.,
2015; Xu et al., 2013; Zhang et al., 2015), yeast (Jovicic et al.,
2015), and mice (Chew et al., 2015; Hukema et al., 2014;
O’Rourke et al., 2015; Peters et al., 2015; Zhang et al., 2016).2 Neuron 90, 1–16, May 4, 2016By production and analysis of mice in which one or both
C9orf72 alleles were inactivated, and multiple transgenic mouse
lines expressing up to 450 C9ORF72 hexanucleotide repeats,
we tested disease mechanism(s) associated with C9ALS/FTD.
Herein we show a repeat-length-dependent gain of toxicity,
while chronic reduction of C9ORF72 does not produce nervous
system disease. Single-dose injection of antisense oligonucleo-
tides (ASOs) that selectively target repeat-containing RNAs
causes a rapid reduction in RNA foci and DPR proteins, while
maintaining overall levels of C9ORF72-encoding mRNAs and
producing a sustained alleviation of behavioral deficits.
RESULTS
Reduction in C9ORF72 Is Well-Tolerated, but
Splenomegaly and Enlarged Lymph Nodes Develop in Its
Absence
To determine the consequence of loss of C9ORF72 function
in vivo, mice were generated in which a LacZ reporter re-
placed exons 2–6 of the endogenous C9orf72 gene (Figure 1A).
As expected, total C9orf72 RNAs and the full-length 54 kD
C9ORF72 protein were reduced to 50% in brains of heterozy-
gous C9orf72+/ mice and were completely absent in homozy-
gous C9orf72/ mice (Figures 1B and 1C). A b-galactosidase
activity assay, used to assess endogenous C9orf72 gene
expression throughout the CNS, revealed broad expression of
C9orf72 not only in neurons of the gray matter as previously re-
ported (Suzuki et al., 2013), but also in glial cells of whitematter in
various CNS regions, including the cerebellum and spinal cord
(Figures S1A and S1B, available online). Further evidence con-
firming substantial expression of the C9orf72 gene in glial cells
was obtained using high-throughput sequencing of translated
RNAs purified from BacTRAP transgenic mice that express
EGFP-tagged ribosomal protein L10a in defined cell populations
(Heiman et al., 2008). C9orf72 RNAs were identified in all three
cell types tested, with relative abundances of 2.5:1:1 in motor
neurons, astrocytes, and oligodendrocytes, respectively (Fig-
ure S1C). No overt neuropathology developed in C9orf72+/ or
C9orf72/ mice, and no increase in GFAP-positive astrocytes
or IBA-1-positive microglia occurred in brain and spinal cord
(Figures S1D and S1E).
The reduction in C9ORF72 to 50% of its normal level,
as reported in C9ALS/FTD patients, was well tolerated with
C9orf72+/ mice surviving into adulthood with a normal body
weight and no signs of disease (Figures 1D–1F). In contrast,
although C9orf72/ mice were born in the expected Mendelian
ratio with no change in survival through 11 months of age, only
7% of mice survived to 20 months of age (Figure 1D). C9orf72
null mice showed reduced body weight (Figure 1E), splenomeg-
aly (Figure 1F), and enlarged cervical lymph nodes (Figure S1F)
by 12 months of age. The spleen size was comparable in
C9orf72+/ mice (80.33 ± 0.88 mg, n = 3, mean ± SEM) versus
wild-type littermates (80 ± 0.41 mg, n = 4) at 18 months of age.
Staining of CD3-positive T lymphocytes and CD45R/B220-pos-
itive B lymphocytes revealed disrupted architectures of the
spleen and cervical lymph nodes in C9orf72/ mice (Figures
S1G and S1H). Despite the enlarged size, the total number of
lymphoid cells was not changed in the spleen, while the number
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Figure 1. Reduction of C9ORF72 Is Well-Tolerated, but Complete Loss of C9ORF72 Induces Premature Death and Splenomegaly
(A) Targeting strategy to generateC9orf72 null micewith exons 2–6 replacedwith b-galactosidase and neomycin (Neo) genes. Schematic shows (upper panel) the
genomic region, (middle panel) targeting construct, and (lower panel) final targeted C9orf72 gene. Filled boxes correspond to exons. Open box represents the
30 untranslated region (30-UTR).
(B) qRT-PCR measurement of mouse C9orf72 RNAs in brains of C9orf72+/+, C9orf72+/, and C9orf72/ mice (n = 6 per group).
(C) Immunoblot demonstrating the levels of the 54 kD mouse C9ORF72 protein. GAPDH was used as a loading control.
(D) Survival curve up to 600 days.
(E) Body weights at 3, 6, and 12 months of age (n = 25 per genotype).
(F) Spleen sizes at 12 months of age.
(G–I) Behavioral performancemeasured at 3, 6, and 12months of age (n = 25 animals per group). (G) Social interactionsmeasured by themean time spent with an
object, in the center, or with a mouse. (H) Social recognition measured by the mean time spent with a familiar mouse, in the center, or with a novel mouse.
(I) Hindlimb grip strength.
(J) Average number of ChAT-positive neurons per section in the anterior horn of lumbar spinal cord in 12-month-old mice (n = 4–5 per group).
(K and L) Resting electromyographic (EMG) recordings (K) andmyogenicmotor-evoked potentials (MMEPs) (L) in 12-month-oldC9orf72mice (n = 5 per genotype)
or in end-stage transgenic mice expressing mutant SOD1G37R (crosshatched bars, n = 2). Error bars represent SEM in biological replicates; n.s., not significant;
*p < 0.05, **p < 0.01 using one-way ANOVA.
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Figure 2. Generation of Multiple BAC Transgenic Mouse Lines Expressing Different Levels of a Human C9ORF72 Transgene with 100–700
GGGGCC Repeats
(A) Schematic of the human BAC containing 450 GGGGCC repeats in the first intron of a truncated humanC9ORF72 gene. The coordinates of the BAC sequence
on the University of California, Santa Cruz Genome Browser (Hg19) are indicated. No other gene is on the BAC.
(legend continued on next page)
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myeloid cells were increased by more than an order of magni-
tude in the cervical lymph nodes (Figure S2A). In addition,
C9orf72 null mice showed decreased hemoglobin and packed
cell volume, decreased percentage of lymphocytes, and in-
creased percentage of neutrophils in blood (Figure S2B).
To determine whether partial or complete loss of C9ORF72
triggered age-dependent cognitive and/or motor deficits, longi-
tudinal assessment of strength, motor coordination, anxiety,
sociability, and learning functions in cohorts of C9orf72+/+,
C9orf72+/, and C9orf72/mice was performed. No behavioral
abnormalities were observed in C9orf72+/ mice at any of the
ages tested (3, 6, and 12 months) (Figures 1G–1I and S2C–
S2H). By 12 months of age, C9orf72 null mice developed mild
social interaction (Figure 1G) and social recognition (Figure 1H)
abnormalities compared with wild-type or heterozygous litter-
mates. In addition, 12-month-old C9orf72/ mice developed
mild motor deficits on a rotarod assay (Figure S2C) without
differences in grip strength, gait, or general activity (Figures 1I,
S2D, and S2E), or loss of ChAT-positive lower motor neurons
(Figure 1J). Resting electromyographic (EMG) recordings were
also normal in the gastrocnemius muscles of mice lacking
C9ORF72, consistent with intact neuromuscular connectivity
(Figure 1K). The amplitudes of myogenic motor-evoked poten-
tials (MMEPs), a measure of connectivity of the entire neuromus-
cular unit, are comparable among C9orf72+/, C9orf72/, and
C9orf72+/+ mice (Figure 1L), in contrast to their almost complete
loss in end-stage SOD1G37R mice. Overall, C9ORF72 reduction
alone is not sufficient to cause C9ALS/FTD-associated pheno-
types in mice.
BAC C9ORF72 Transgenic Mouse Lines with Different
Repeat Sizes and Expression Levels
To test a potential gain of toxicity from repeat expansions, trans-
genic mice were generated that express a bacterial artificial
chromosome (BAC) with the human expanded C9ORF72 gene
from a C9ALS patient. The BAC includes 140 kb of sequence
50 to the C9ORF72 exon 1a (including what is likely to be the
complete promoter region) and exons 1–5 of the gene. The
BAC does not encode the 54 kD C9ORF72 protein (Figure 2A)
(DeJesus-Hernandez et al., 2011). The interferon kappa gene,
which lies within 23 kb 30 of C9ORF72 on human chromosome
9, is not present, nor is any other known gene besidesC9ORF72.
Thirty-two founder mice were generated in a C57BL6/C3H
hybrid background and backcrossed to C57BL/6 mice. Foun-
ders from eight lines had either multiple repeat sizes that
separated in subsequent generations (Figure 2B) or multiple(B–D) Genomic DNA blot analysis of tail DNA from (B) founder (F0) and F1 transg
C9ORF72 alleles; (C) twelve different mice of lines 1, 8, 10, and 11 (redesignatedC
generations in line C9450B.
(E) Repeat lengths determined by genomic DNA blotting using DNA from the CN
(F) HumanC9ORF72 RNA in cortex of transgenic mice measured by qRT-PCR, no
genomic DNA blots. Numbers in pink represent transgenes with different repeat
(G) Expression levels of total (human plus mouse) C9ORF72 RNAs in the cortex of
C9orf72 RNA.
(H) Level of repeat-containing C9ORF72 RNA variants in the cortex measured by
(I and J) Levels of (I) total C9ORF72 RNAs (human plus mouse) normalized to C
measured by qRT-PCR in the cortex of heterozygous and homozygous C9450C mtransgene copies with different repeat lengths at the same locus
that segregated together (Figure S3A). Eleven lines contained a
single repeat size that was stably inherited from filial (F)0 to F5
generations in the large majority of mice (Figures 2B–2D), albeit
analysis of 42 littermates from one line identified three repeat
contraction events (Figure S3B). At most, modest expansion
was found within the CNS or peripheral tissues (Figures 2E,
S3C, and S3D), in contrast to humans, for whom somatic hetero-
geneity and repeat instability have been reported, especially
within the CNS (van Blitterswijk et al., 2013).
Transgene expression levels were examined in 19 lines car-
rying between 110 and 790 repeats (Figure 2F). Recognizing
that transgenes with multiple repeat sizes would preclude corre-
lation analyses of repeat-length- and expression-associated
toxicity, we selected four lines with defined repeat lengths and/
or different transgene expression levels: line 8 with110 repeats
(hereafter designated C9110) and three lines expressing various
levels of RNAs but each containing 450 repeats (lines 1, 10,
and 11, designated C9450A, C9450B, and C9450C, respectively).
C9110 and C9450B have comparable levels of transgene expres-
sion but different repeat sizes, whereas C9450B has a similar
repeat size as C9450A, but higher transgene expression (Figures
2C and 2F). C9ORF72 transgene-encoded RNAs were three to
four times the level of endogenous mouse C9orf72 RNA in lines
C9110, C9450B, and C9450C, and equal to endogenous C9orf72
in line C9450A (Figure 2G). Endogenous C9orf72 RNAs were
unchanged in all lines. Similar to total C9ORF72 RNAs, repeat-
containing RNAs (measured by qRT-PCR with variant-specific
primers; Figure S3E) were higher in C9450B mice than C9450A
mice. Repeat-containing RNAs were three times higher in
C9110 than C9450B mice (Figure 2H), despite comparable total
C9ORF72 RNA levels (Figures 2G and S3F). Breeding produced
homozygous C9450C mice with C9ORF72 expression 12 times
the level of mouse C9orf72 (Figures 2I and 2J).
Repeat Size- and Dose-Dependent Accumulation of
Sense and Antisense RNA Foci
RNAs transcribed from both sense (GGGGCC) and antisense
(GGCCCC) strands ofC9ORF72 have been reported to accumu-
late into RNA foci in cultured cells and postmortem tissues from
C9ALS/FTD patients (Gendron et al., 2013; Lagier-Tourenne
et al., 2013; Mizielinska et al., 2013; Zu et al., 2013). Use of fluo-
rescence in situ hybridization detected sense and antisense foci
in all three mouse lines expressing 450 repeats. Foci were found
throughout the CNS, including the frontal cortex, hippocampus,
cerebellum, and spinal cord, as early as 2 months of age (Fig-
ure 3A) and were not observed in wild-type mice (Figure S3G).enic mice from lines 9 or 15 and DNA from human fibroblasts (Hu) with normal
9450A, C9110, C9450B, andC9450C, respectively); and (D)mice from F0, F2, and F5
S and peripheral tissues of a C9450B mouse.
rmalized to C9450A mice. Numbers above bars are repeat lengths measured by
lengths at the same locus that segregated together.
C9110, C9450A, C9450B, and C9450C mice normalized to the level of endogenous
qRT-PCR and normalized to levels in C9450A mice.
9orf72 levels in wild-type littermates, or (J) repeat-containing C9ORF72 RNA
ice. Error bars represent SEM from 3 to 5 biological replicates per group.
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Figure 3. Repeat Size- and Dose-Dependent Accumulation of Sense and Antisense RNA Foci in C9ORF72 Transgenic Mice
(A) FISH detection of sense and antisense RNA foci (arrows) in 2-month-old C9450B mice. DNA was stained with DAPI.
(B–E) Numbers of sense and antisense foci (per 100 nuclei) in hippocampal dentate gyrus of (B and C) 2-month-old C9110, C9450A, and C9450B mice, and (D and E)
6-month-old heterozygous and homozygous C9450C mice. Error bars represent SEM in 3–5 biological replicates. *p < 0.05, **p < 0.01 using Student’s t test.
(F) Quantification of sense RNA foci per nucleus in hippocampal dentate gyrus of 6-month-old heterozygous and homozygous C9450C mice.
(G) qRT-PCRmeasurement of human and mouseC9ORF72 RNAs in cortex of 2-, 6-, and 16-month-old C9450B mice, normalized to wild-type littermates (n = 2–4
per group).
(H) Numbers of sense foci (per 100 nuclei) in hippocampal dentate gyrus of 2-, 6-, and 16-month-old C9450B mice. Error bars represent SEM in 2–4 biological
replicates. n.s., not significant using one-way ANOVA.
Please cite this article in press as: Jiang et al., Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense Ol-
igonucleotides Targeting GGGGCC-Containing RNAs, Neuron (2016), http://dx.doi.org/10.1016/j.neuron.2016.04.006Sense foci were most abundant in the frontal cortex, followed
by the hippocampal dentate gyrus, retrosplenial cortex, and
molecular layer of the cerebellum (Figure S3H). An unexpected,
surprisingly strong influence of repeat length on foci formation
was uncovered: whereas mice with 450 repeats developed foci
(Figure 3A), neither sense nor antisense foci were detected in
any brain region, or at any age, in C9110 mice with 110 repeats
(Figures 3B and 3C). This was despite the fact that transgene6 Neuron 90, 1–16, May 4, 2016expression in C9110 mice was 3.5 times that of endogenous
C9orf72RNAs (seven times the level of RNA from a single endog-
enous C9orf72 allele) (Figure 2G) and that levels of repeat-con-
taining RNAs in C9110 mice were three and six times higher
than in C9450B and C9450A mice, respectively (Figure 2H).
Doubling the level of 450 repeat-containing sense strand
RNAs (compare RNA levels in C9450B versus C9450A; Figures
2G and 2H) doubled sense foci accordingly (Figure 3B). Similarly,
Please cite this article in press as: Jiang et al., Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense Ol-
igonucleotides Targeting GGGGCC-Containing RNAs, Neuron (2016), http://dx.doi.org/10.1016/j.neuron.2016.04.006doubling repeat-containing RNAs by generating homozygous
C9450C mice more than doubled the overall number of sense
foci (Figure 3D) and the number of foci per cell (Figure 3F). The
proportion of cells that developed sense foci also increased
from 52% in the dentate gyrus of heterozygous C9450C mice
to 81% in homozygous mice (Figure S3I), and some cells accu-
mulated more than 30 sense foci (Figure 3F). Transgene expres-
sion and foci burden remained constant with age (Figures 3G
and 3H).
Antisense RNAs from the human C9ORF72 transgene, identi-
fied using a strand-specific RT-PCR strategy (Figures S3K and
S3L), also accumulated into RNA foci (Figure 3A). As with sense
foci, antisense foci increased with increased repeat length (Fig-
ure 3C) and RNA expression level, with both the overall number
of antisense foci (Figure 3E) and the percentage of cells with foci
(Figures S3I and S3J) nearly doubling in homozygous versus
heterozygous C9450C mice.
Age-, Repeat-Length-, and Expression-Dependent
Cytoplasmic Inclusions of DPR Proteins
Inclusions of DPR proteins produced by RAN translation from
GGGGCC or GGCCCC repeats are a neuropathological hallmark
of C9ALS/FTD (Ash et al., 2013; Gendron et al., 2013; Mori et al.,
2013a, 2013c; Zu et al., 2013). As in human patients, perinuclear,
cytoplasmic aggregates of sense strand RNA-encoded poly(GA),
poly(GP), or poly(GR) proteins were detected in multiple CNS re-
gions in C9450C mice as young as 3 months of age (Figures 4A
and 4B). Poly(GA) and poly(GP) aggregates in 22-month-old
C9450C mice were most abundant in the retrosplenial cortex,
followed by the hippocampal dentate gyrus and frontal cortex
(Figures 4C and S4A). Fewer poly(GA) aggregates were observed
in the cerebellum (Figure S4B) or spinal cord. Dot blot assay
confirmed accumulation of poly(GP) in cortical lysates from
6-month-oldC9450Cmice (Figure S4C). As inC9ALS/FTDpatients
(Mori et al., 2013a), DPR proteins coaggregated into common,
p62-containing inclusions (Figures 4D, 4E, and S4D). Antisense
strand-encoded poly(PR) and poly(PA) proteins have only been
detected in rare aggregates in patient samples (Gendron et al.,
2013; Mackenzie et al., 2015; Mori et al., 2013a; Schludi et al.,
2015; Zu et al., 2013). None were detected in C9 mice of any
line or at any age.
Similar to RNA foci formation, DPR protein expression was
dependent on repeat length, as established by immunoassay
for quantitative measurements of poly(GP) (Su et al., 2014).
Although C9110 mice expressed a 3-fold higher level of repeat-
containing C9ORF72 RNAs than C9450B mice (Figure 2H), no
poly(GP) was detected in 2% SDS-soluble homogenates pre-
pared from tissues of various neuroanatomical regions from
C9110 mice, while poly(GP) was easily detected in mice express-
ing 450 repeats (Figure 4F). As expected, more poly(GP) was de-
tected in mice with higher C9ORF72 RNA expression (compare
C9450A and C9450B mice; Figure 4F; and homozygous C9450C
versus age-matched heterozygotes; Figure 4G).
SDS-soluble poly(GP) decreased with age in C9450A and
C9450B mice (Figure 4H), despite constant transgene expression
(Figure 3G), indicating that DPR proteins may become insoluble
over time. Consistent with this notion, poly(GA) aggregatedmore
in the retrosplenial cortex (Figure 4I) and hippocampus (Fig-ure S4E) as mice aged, and the size of poly(GA) inclusions
increased over time (Figure 4J). Age-dependent increases in
the number and size of poly(GP) and poly(GR) aggregates were
also detected (Figures S4F and S4G). In addition, more cells
accumulated DPR protein aggregates in 3-month-old C9450C ho-
mozygous mice compared to heterozygous mice, and the abun-
dance of such aggregates was increased at 6 months of age
(Figures 4I, 4K, S4F, and S4G).
Age-Dependent Cognitive Impairment in C9 Mice
Expressing 450 Repeats
C9 transgenic mice were tested for age-dependent disease.
No significant motor deficits or weight loss were observed by
18 months of age in two mouse lines expressing 450 repeats
(C9450B or C9450C; Figures 5A–5C, S5A, and S5B). By 12 months
of age, no loss of ChAT-positive lowermotor neurons (Figures 5D
and 5E) or increased glial activation (Figure S5C) was detected in
the spinal cord of C9450C mice, which express the highest levels
of transgene. Functional innervation and connectivity of the
entire neuromuscular unit were normal, as measured by resting
EMG recordings and MMEP amplitudes, respectively, in 12-
month-old C9110 and C9450C mice (Figures S5D and S5E). There
was no loss of CTIP-2-positive upper motor neurons in layer 5
of the motor cortex in either line (Figure S5F).
Cognitive and behavioral dysfunction, however, developed in
an age-dependent manner. While 4-month-old C9450B mice per-
formed aswell as wild-type littermates in an assay that measures
spatial learning and memory (the Barnes maze), both C9450B and
C9450C lines developed deficits by 12 months of age that were
sustained to 18 months (Figure 6A). A second spatial-learning
assay (the radial arm maze) confirmed a working memory deficit
at 12 and 18 months of age in C9450B and C9450C mice (Fig-
ure 6B). Aged C9450B and C9450C male mice also displayed
abnormalities in two ‘‘anxiety’’ assays, amarble burying test (Fig-
ure 6C) and an elevated plus maze (Figure 6D). The spatial
learning and anxiety abnormalities were not accompanied by
behavioral differences in social interaction, social recognition,
or social communication, nor did assays of novel object re-
cognition, fear conditioning, and serial reversal learning uncover
any impairment (Figures S6C–S6H).
Recognizing the crucial role of the hippocampus in spatial
learning and memory (Sharma et al., 2010), we tested the C9
mice for age-dependent hippocampal neuron loss. Blinded
quantification in two hippocampal regions (the dentate gyrus
and CA1 region) of 4- and 12-month-old C9450B and C9450C
mice identified mild, age-dependent neuronal loss (Figures 6E
and 6F). Neuronal loss was repeat-length dependent, as no
loss was seen in C9110 mice that expressed higher levels of
repeat-containing RNAs than C9450C mice (Figure S7A). No
astrogliosis or microgliosis was observed, and neuronal loss
was region specific, as the neuronal density in the retrosplenial
cortex remained unchanged (Figure S7A). Although levels of
both sarkosyl-soluble and sarkosyl-insoluble (but urea-soluble)
phosphorylated TDP-43 (pTDP-43) were significantly increased
in 22-month-old C9450C mice (Figure S7C), no TDP-43 misloc-
alization or aggregation was observed (Figure S7B). Simi-
larly, no mislocalized, discontinuous, or punctate aggregates of
RanGAP1 or Lamin B (Figures S7D and S7E) were identified.Neuron 90, 1–16, May 4, 2016 7
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Figure 4. Repeat Size- and Expression-Dependent Production of Sense-Strand-Encoded DPR Proteins Is Associated with Age-Dependent
Formation of Cytoplasmic Inclusions
(A) Poly(GA), poly(GP), and poly(GR) perinuclear aggregates (arrows) detected by immunohistochemistry in the retrosplenial cortex of 6-month-old homozygous
C9450C mice. Nuclei were stained with haemalum.
(B) Poly(GA) aggregates (arrows) in different CNS regions of 6-month-old homozygous C9450C mice.
(C) Percent of cells containing poly(GA) or poly(GP) inclusions in frontal cortex (Ftx), hippocampus (Hip), and retrosplenial cortex (RSC) of 22-month-old
heterozygous C9450C mice (n = 2–4 biological replicates).
(D and E) (D) Aggregates positive for (green) poly(GP), (red) poly(GA), or (yellow) both, and (E) (green) poly(GP) and (red) P62-positive inclusions identified by
immunofluorescence in retrosplenial cortex of 6-month-old homozygous C9450C mice. DNA is stained with DAPI.
(legend continued on next page)
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Figure 5. No Motor Neuron Loss and Motor Deficits in C9ORF72 Transgenic Mice with 450 Repeats
(A–C) (A) Motor performance on a rotarodmeasured by latency to fall, (B) hindlimb grip strength, and (C) body weight of 4-, 12-, and 18-month-old wild-type (WT),
C9450B, and C9450C mice.
(D) Choline acetyltransferase (ChAT)-positive motor neurons detected by immunofluorescence in the anterior horn of lumbar spinal cord of 12-month-old WT,
C9110, and C9450C mice.
(E) Average number of ChAT-positive neurons per section. Error bars represent SEM in n = 4–5 animals per group. n.s., not significant using one-way ANOVA.
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Behavioral Deficits in C9 Mice
ASOsmediate cleavage of target RNAs through action of the pri-
marily nuclear enzyme RNase H, and ASO therapy has gone to
clinical trial for ALS (Miller et al., 2013; Smith et al., 2006) and
at least two neurodegenerative disorders linked to repeat expan-
sions: myotonic dystrophy (Wheeler et al., 2012) and Hunting-
ton’s disease (Kordasiewicz et al., 2012). To test whether in vivo
administration of ASOs canmediate RNase H-dependent, selec-
tive reduction of C9ORF72 hexanucleotide repeat-containing
RNAs in the rodent CNS, 3-month-old C9450B mice were treated
with a single intraventricular bolus injection of ASOs targeting
human C9ORF72 RNAs or a control ASO that does not have
any target in the mouse genome (Figure 7A). One C9ORF72
ASO (ASO1) was complementary to a sequence that partially
overlaps the 50 end of the hexanucleotide expansion and specif-
ically targets repeat-containing C9ORF72 RNA variants. A sec-(F–H) Levels of poly(GP) soluble in 2% SDS measured by immunoassay in (F) cere
and spinal cord of 6-month-old heterozygous and homozygous C9450C mice; and
replicates).
(I) Poly(GA) aggregates (arrows) identified by immunohistochemistry in retrosplen
noted ages.
(J) (Left panel) Percent of cells containing poly(GA) aggregates and (right panel) av
biological replicates).
(K) Percent of cells with poly(GA) inclusions in retrosplenial cortex of heterozygo
*p < 0.05, **p < 0.01 using Student’s t test.ond ASO (ASO2) hybridizes within exon 2 and thus targets all
C9ORF72 RNA variants (Figure 7B). Four weeks after a single
injection, both ASO1 and ASO2 decreased repeat-contain-
ing C9ORF72 RNA levels in the cortex and spinal cord to
20%–40% of levels in control ASO-treated mice (Figure 7C).
As expected, ASO2 decreased total and exon 1b-containing
C9ORF72 RNAs by 40%–60%. However, ASO1, which targets
repeat RNA, preserved exon 1b-containing, C9ORF72 protein-
encoding RNAs (Figure 7E) and 80% of total C9ORF72 RNAs
(Figure 7D).
Within 4 weeks after a single injection of either ASO1 or ASO2,
the number of sense foci was reduced to 40%–45% (Figures 7F
and 7G). Antisense RNA foci remained unchanged (Figure 7F).
Both SDS-soluble poly(GP) and poly(GA) were decreased to
almost undetectable levels in the cortex and spinal cord (Figures
7H and 7I). The profound reduction of poly(GP), which can be
translated from sense or antisense strand RNAs, demonstratesbellum of 3-month-old C9110, C9450A, and C9450B mice; (G) cerebellum, cortex,
(H) during aging in the cerebellum of C9450A and C9450B mice (n = 2–5 biological
ial cortex of heterozygous or homozygous C9450C mice or wild-type mice at the
erage size of poly(GA) inclusions in retrosplenial cortex of C9450C mice (n = 2–3
us and homozygous C9450C mice (n = 3 per group). Error bars represent SEM.
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Figure 6. Age-Dependent Increased Anxiety and Impaired Cognitive Function in C9ORF72 Mice with 450 Repeats
(A and B) Behavioral performances in WT, C9450B, and C9450C mice at 4, 12, and 18 months of age (n = 25 mice per group at 4 months and n = 16 [WT], n = 14
[C9450B], and n = 10 [C9450C] at 12 and 18months of age). (A) Spatial learning andmemory performance on a Barnes maze showing the number of errors in finding
the escape chamber at days 1–3, 4–6, and 7–9. (B) Working memory performance on a radial maze showing errors per trial over 10 days of testing.
(C and D) Anxiety-related behaviors in WT, C9450B, and C9450C male mice at 4, 12, and 18 months of age (n = 11 [WT] and n = 13 [C9450B] at 4 months, and n = 9
[WT], n = 4 [C9450B], and n = 7 [C9450C] at 12 and 18 months of age). (C) Anxiety-related behavior determined by marble burying test showing the percent of
marbles buried during a 20 min trial, and (D) elevated plus maze showing the percent of time spent on the open arm.
(E and F) (E) Representative images and (F) quantification of DAPI-positive nuclei in the hippocampal dentate gyrus and CA1 region in 4- and 12-month-old WT,
C9450B, and C9450C mice (n = 4–5 per group). Error bars represent SEM, n.s., not significant, *p < 0.05 and **p < 0.01 using one-way ANOVA.
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Selective reduction of repeat-containing RNAs with attenu-
ated RNA foci and RAN translation was confirmed by single-10 Neuron 90, 1–16, May 4, 2016dose injection of two additional ASOs (ASO3 and ASO4) target-
ing sequences 50 to the expansion within C9ORF72 intron 1
(Figures 7B and S8A). Two weeks after treatment, repeat-con-
taining C9ORF72 RNAs in cortex and spinal cord were reduced
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Figure 7. Sustained Reduction in RNA Foci
and DPR Proteins from a Single Dose of
ASOs Targeting C9ORF72 Repeat-Contain-
ing RNAs
(A) Schematic of injected ASOs targeting the sense
strand C9ORF72 transcripts for degradation in
3-month-old C9450B mice.
(B) Schematic of the C9ORF72 gene showing the
GGGGCC repeats within the first intron, the two
transcription initiation sites (arrows), the posi-
tions of five ASOs, and primers for detection (by
qRT-PCR) of various C9ORF72 RNAs.
(C–E) Expression of (C) repeat-containing, (D) to-
tal, and (E) exon 1b-containing C9ORF72 RNAs
determined by qRT-PCR in mice treated either
with ASO1 targeting only the repeat-containing
RNAs, ASO2 targeting all C9ORF72 variants, or a
control ASO.
(F and G) (F) Number of sense and antisense foci
(per 100 nuclei) determined by FISH and (G)
quantification of sense foci per nucleus in hippo-
campal dentate gyrus.
(H and I) Levels of (H) poly(GP) or (I) poly(GA) in the
cortex and spinal cord of C9450B mice treated with
ASO1, ASO2, or a control ASO, as measured by
immunoassay. Error bars represent SEM in n = 5–6
biological replicates. *p < 0.05, **p < 0.01, n.s. not
significant using one-way ANOVA.
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maining at 80% of their initial level (Figures S8B and S8C). Sense
foci were reduced by half; antisense foci were unaffected.
SDS-soluble poly(GP) levels were reduced by more than 80%
in cortex and 50% in spinal cord (Figure S7D), and poly(GP)
aggregates, quantified in a blinded fashion, were significantly
decreased in ASO3- or ASO4-treated mice (Figures S8E and
S8F). Thus, intron 1-targeting ASOs rapidly decrease both solu-
ble and insoluble DPR proteins throughout the mouse CNS.
Finally, 9-month-old C9450B mice were injected with an ASO
targeted to repeat-containing RNAs (Figure 8A). Repeat-contain-
ing C9ORF72 RNAs in the cortex and spinal cord were sharplyreduced (to 23% and 12% of control
levels, respectively) within 2 weeks of
treatment (Figure 8B). Consistent with
our assays with an independent cohort
(Figures 6A–6D), C9450B mice injected
with a control ASO developed increased
anxiety (in marble burying test and
elevated plus maze) and impaired cogni-
tion (in Barnes and radial mazes) (Figures
8C–8F). Single-dose ASO injection at
9 months alleviated these age-depen-
dent deficits (Figures 8C–8F). In fact, at
15 months (6 months after injection), the
beneficial effects were sustained, with a
trend suggestive of further improvement.
Correspondingly, SDS-soluble poly(GP)
and poly(GA) levels remained lower in
16-month-old mice treated with the
repeat-targeting ASO (Figure 8H), eventhough repeat-containing C9ORF72 RNA levels had recovered
to their initial level (Figure 8G).
DISCUSSION
A key question regarding pathogenic mechanisms in C9ALS/
FTD has been whether the repeat expansion causes disease
through loss of C9ORF72 function, gain of toxicity from repeat
RNA, or both. By producing and analyzing mice with a chronic
reduction of C9ORF72 or that express the human C9ORF72
gene with different sizes of expanded repeats, we have identified
gain of toxicity as a central disease mechanism in a mammalianNeuron 90, 1–16, May 4, 2016 11
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Figure 8. Single-Dose ASO Treatment Alle-
viates Age-Dependent Behavioral Deficits
in C9ORF72 Mice Expressing 450 Repeats
(A) Schematic of the experimental procedure for a
single-dose ASO targeting degradation of the
sense strand C9ORF72 RNA in 9-month-old
C9450B mice.
(B) Expression of repeat-containing C9ORF72
RNAs was determined by qRT-PCR 2 weeks after
injection of ASO5 or control ASO (n = 6 per group).
(C and D) Anxiety-related behaviors determined by
(C) marble burying test and (D) elevated plus maze
in 12- and 15-month-old WT and C9450B mice
treated with either control ASO or ASO5 (n = 5–7
per group).
(E and F) Cognition-related behaviors determined
on (E) a Barnes maze and (F) a radial maze in 12-
and 15-month-old WT and C9450B mice treated
with either control ASO or ASO5 (n = 10–13 per
group).
(G and H) (G) Expression of repeat-containing
C9ORF72 RNAs and (H) levels of poly(GP) or
poly(GA) proteins in the cortex of 16-month-old
C9450B mice treated at 9 months with ASO5 or
control ASO. Error bars represent SEM in biolog-
ical replicates *p < 0.05, **p < 0.01, n.s. not sig-
nificant, using Student’s t test.
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two independent lines developed age-dependent, anxiety-like
behavior and impaired cognitive function by 12 months of age,
accompanied by mild hippocampal neuronal loss. In contrast,
mice hemizygous for C9ORF72 that express 50% of C9orf72
mRNA, as observed in C9ALS/FTD patients (DeJesus-Hernan-
dez et al., 2011; Gijselinck et al., 2012; van Blitterswijk et al.,
2015), did not develop an ALS/FTD-like phenotype or any other
phenotype in the CNS or periphery. Hence, by a systematic
comparison of multiple mouse lines, we now demonstrate that
reduction of C9ORF72 expression is not sufficient to trigger neu-
rodegeneration in mice, while pathological hallmarks of C9ALS/
FTD, neuronal loss and cognitive dysfunction develop in mice
expressing expanded repeat RNA.
The function of the 54 kD C9ORF72 protein has not been es-
tablished, but its sequence homology to the DENN protein family
predicts a possible role in regulating membrane trafficking (Farg
et al., 2014; Levine et al., 2013; Zhang et al., 2012). The C9orf72
gene is expressed not only in the CNS but also in peripheral
tissues, including spleen (Suzuki et al., 2013), bonemarrow, lym-
phocytes, and macrophages (BioGPS data; http://biogps.org/).12 Neuron 90, 1–16, May 4, 2016By disrupting both C9orf72 alleles, we
determined that complete elimination of
C9ORF72 from mice produces spleno-
megaly, enlarged cervical lymph nodes,
and premature death. While loss of
C9ORF72 during embryonic develop-
ment has been reported to produce
motor deficits in zebrafish (Ciura et al.,
2013) and C. elegans (Therrien et al.,
2013), systemic (our work here andAtanasio et al., 2016; O’Rourke et al., 2016) or nestin-cre (Kop-
pers et al., 2015)-mediated ablation of C9orf72 in mice is not
associated with motor degeneration, defects in motor function,
or altered survival. In addition, no loss-of-function mutations in
C9ORF72, including nonsense or frameshift mutations, have
been linked to ALS or FTD (Harms et al., 2013), and reduced
expression of expanded RNAs following hypermethylation of
the C9ORF72 promoter may actually be neuroprotective (Liu
et al., 2014; McMillan et al., 2015; Russ et al., 2015). While our
studies reinforce conclusions that C9ORF72 plays an important
role in immune cells (Atanasio et al., 2016; O’Rourke et al., 2016),
chronic reduction of C9ORF72 alone is not sufficient to cause
ALS/FTD symptoms inmice. A key remaining question, now test-
able with the mice we report here, is whether a reduction in
C9ORF72 synergizes with repeat-mediated gain of toxicity to
potentiate disease.
Our analysis uncovered an unexpected association between
hexanucleotide repeat length and accumulation of RNA foci
and DPR proteins. When expressed at seven times the level of
an endogenousC9orf72 allele, no detectableDPRproteins accu-
mulate in mice expressing 110 repeats (Figure 4F). Conversely,
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soluble DPR proteins (Figures 4F–4H) and insoluble aggregates
(Figures 4I–4K). That no DPR proteins were detected in C9110
mice could be due to (1) RAN translation initiation of short repeats
being less efficient than of long repeats; (2) shorter DPR proteins
having shorter half-lives than longer DPR proteins; (3) shorter
repeat-containing RNAs being less effectively transported to
the cytoplasm, the presumed site of RAN translation; or (4) a
combination of options 1–3.
While a prior study demonstrated that robust adeno-associ-
ated-virus-mediated expression of 66 GGGGCC repeats led to
the aggregation of DPR proteins throughout the murine CNS
(Chew et al., 2015), we demonstrate here that expression of a
short repeat does not generate such pathology in mouse brain
when expressed at seven times the levels of RNA from a single
C9orf72 allele. Not only do long and short repeats have differing
capacities to generate DPR proteins, long and short DPR
proteins have different intracellular localization and aggregation
profiles. For instance, DPR proteins translated from 66 repeats
produced a level of accumulated poly(GP) that reached 1.8%
of total brain protein by 6months of age and formed primarily nu-
clear aggregates (Chew et al., 2015), whereas we and others
(O’Rourke et al., 2015; Peters et al., 2015) have shown that in
mice with 400–500 repeats, DPR proteins form cytoplasmic in-
clusions similar to those observed in C9ALS/FTD patients. Short
DPR proteins are likely to be more soluble and sufficiently small
to freely diffuse through nuclear pores, thereby facilitating the in-
tranuclear aggregation of DPR proteins seen in mice expressing
66 repeats (Chew et al., 2015). Similarly, the nucleolar disruption
and acute toxicity resulting from exposing cultured cells to 10 mM
of 20-mer poly(PR) or poly(GR) proteins (Kwon et al., 2014) differ
markedly from the primarily cytoplasmic aggregates observed
in mice expressing 450 repeats and C9ALS/FTD patients (Ash
et al., 2013; Gendron et al., 2013; Mackenzie et al., 2015; Mori
et al., 2013a; Zu et al., 2013).
While theminimal pathogenic repeat size inC9ORF72 patients
is not established, somatic expansion can take the germline-
transmitted repeat to 3,000–5,000 repeats in the most affected
brain regions (Gijselinck et al., 2015; van Blitterswijk et al.,
2013). We have found minimal somatic expansion in either the
CNS or peripheral tissues of mice. Also differing from C9ALS/
FTD patients, our C9450mice did not display TDP-43mislocaliza-
tion or aggregation, although increased levels of phosphorylated
TDP-43 were detected. In addition, we did not observe misloc-
alization of proteins involved in nucleocytoplasmic transport.
Lack of these features may explain the relatively mild phenotype
observed in our transgenic mice despite expression of up to 24
times a single endogenous C9orf72 allele. While abundant
RNA foci did not increase with age in our mice, an age- and
repeat-length-dependent increase in the number and size of
cytoplasmic DPR aggregates was seen, with soluble poly(GP)
levels decreasing with age (Figure 4H). In C9ALS/FTD, the
anatomical distribution of DPR protein pathology does not corre-
late with neurodegeneration (Schludi et al., 2015). These findings
suggest that certain neuroanatomical regions are less suscepti-
ble to DPR proteins, or that soluble DPR proteins are toxic and
DPR protein aggregates are neuroprotective. In support of the
latter, poly(GA) can recruit poly(GR) into inclusions and partiallydecrease poly(GR) toxicity in Drosophila and cultured cell
models (Yang et al., 2015). On the other hand, aggregation of
poly(GA) was recently reported to be necessary for its toxicity,
which is mediated through sequestration of HR23 and nucleocy-
toplasmic transport proteins (Zhang et al., 2016).
Despite uncertainty about the contributions of RNA foci or
DPR proteins to neurodegeneration, an ‘‘on mechanism’’ ther-
apy would be one that reduces repeat-containing RNAs, thereby
attenuating both potential toxicities. We have established the
potency of multiple ASOs for selective reduction of repeat-con-
tainingC9ORF72RNAs in themammalian CNSwhile havingmin-
imal effect on total C9ORF72 RNAs. Importantly, single-dose
ASO (1) significantly mitigated the accumulation of sense RNA
foci (without increasing antisense foci) and of poly(GP) and
poly(GA) proteins and (2) significantly attenuated the develop-
ment of behavioral deficits even 6 months after treatment.
Thus, our studies establish a repeat-dependent gain of toxicity
as a crucial pathological mechanism of C9ALS/FTD and, most
importantly, validate the feasibility of employing ASO therapy
to mitigate the toxicity from repeat RNAs without exacerbating
a potential loss of C9ORF72 function.
EXPERIMENTAL PROCEDURES
Please see the Supplemental Experimental Procedures for more information
Generation of C9ORF72 BAC Transgenic Mice
The human BAC construct expressing a truncated C9ORF72 gene with 450
repeat expansions was obtained from BACPAC resource center at Children’s
Hospital Oakland Research Institute (clone ID: CH523-111K12) and was in-
jected into the pronuclei of fertilized C57BL6/C3H hybrid eggs and implanted
into pseudo-pregnant female mice. Mice used in this report were then back-
crossed to C57BL/6 for a minimum of three generations. All experimental pro-
cedures were approved by the Institutional Animal Care and Use Committee of
the University of California, San Diego.
RNA Extraction and qRT-PCR
Procedures are detailed in the Supplemental Information. Primers and probe
sequences are listed in Table S1.
Generation of Antibodies Recognizing DPR Proteins
Peptide antigens (C-Ahx-(GA)8-amide, C-Ahx-(GR)8-amide, C-Ahx-(PR)8-
amide, C-Ahx-(GP)8-amide, and C-Ahx-(PA)8-amide) were used to immunize
rabbits to generate antibodies against DPR proteins. Pre-immune serum from
each rabbit was tested using peptide antigens and tissue from C9ALS/FTD
cases by immunoblot and immunohistochemistry, respectively, and confirmed
negative. Antiserum or affinity-purified antibodies were used. Antibodies spe-
cific for each DPR protein are herein annotated Rb4333 poly(GA), Rb4335 pol-
y(GP), Rb4995 poly(GR), Rb15898 poly(PA), and Rb15986 poly(PR).
Immunofluorescence Staining and X-gal Staining
Sections from paraformaldehyde-fixed tissues were stained using standard
protocols with antibodies against GFAP (Chemicon, 1:1000), IBA1 (Wako,
1:500), ChAT (Millipore, 1:300), NeuN (GeneTex, 1:1000), CTIP2 (Abcam,
1:500), poly(GA) (Rb4333, 1:1000), poly(GP) (Rb4335, 1:1000), poly(GR)
(Rb4995, 1:1000), poly(PR) (Rb15986, 1:100), poly(PA) (Rb15989, 1:100),
TDP-43 (Proteintech, 1:500), RanGAP1 (Santa Cruz, 1:500), Lamin B (Santa
Cruz, 1:20,000), and P62 (Abnova, 1:100). Confocal images were acquired
on a Nikon Eclipse laser scanning confocal microscope using the Nikon
EZ-C1 software. LacZ activity was assessed with X-gal staining solution
(1.0 mg/mL of X-gal, 5 mM potassium ferrocyanide, and 2 mM MgCl2) for
12 hr at 37C. The sections were examined and photographed with a
Nanozoomer.Neuron 90, 1–16, May 4, 2016 13
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Intra-cerebroventricular (ICV) stereotactic injections of 10 mL of ASO solution,
corresponding to a total of 350 mg of ASOs (Ionis Pharmaceuticals), were
administered into the right ventricle using the following coordinates: 0.2 mm
posterior and 1.0 mm lateral to the right from the bregma and 3 mm deep.
Mice were treated either with PBS; a control ASO; ASOs targeting total
C9ORF72 (ASO2); or repeat-containing C9ORF72 variants (ASO1, ASO3,
ASO4, or ASO5). The sequences of the ASOs are available in Table S2.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
eight figures, and two tables and can be found with this article online at
http://dx.doi.org/10.1016/j.neuron.2016.04.006.
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